Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

NEWRON PHARMACEUTICALS SPA (NWRN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/16/2019 01/17/2019 01/18/2019 01/21/2019 01/22/2019 Date
7.42(c) 7.5(c) 7.48(c) 7.2(c) 7 Last
47 001 20 515 14 572 15 288 18 483 Volume
+3.20% +1.08% -0.27% -3.74% -2.78% Change
More quotes
Financials (EUR)
Sales 2018 6,01 M
EBIT 2018 -19,1 M
Net income 2018 -21,7 M
Finance 2018 43,0 M
Yield 2018 -
Sales 2019 12,5 M
EBIT 2019 -23,6 M
Net income 2019 -25,4 M
Finance 2019 21,7 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 12,5x
EV / Sales2019 7,69x
Capitalization 118 M
More Financials
Company
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company... 
More about the company
Surperformance© ratings of Newron Pharmaceuticals SpA
Trading Rating : Investor Rating :
More Ratings
Latest news on NEWRON PHARMACEUTICALS SPA
01/17NEWRON PHARMACEUTICALS : - Commercialization partner Zambon together with Valeo ..
AQ
01/16NEWRON PHARMACEUTICALS : Commercialization Partner Zambon Together with Valeo Ph..
BU
2018NEWRON PHARMACEUTICALS : Zambon announces approval and artg listing of safinamid..
PU
2018NEWRON PHARMACEUTICALS : Hosts its 2018 R&D Day in New York City
BU
2018NEWRON PHARMACEUTICALS : bags 40m EIB loan
AQ
2018INVESTMENT PLAN FOR EUROPE : EIB backs Italian CNS drug developer Newron Pharmac..
PU
2018NEWRON PHARMACEUTICALS : to Webcast Presentations from 2018 R&D Day Event on Oct..
BU
2018NEWRON PHARMACEUTICALS : Meiji Seika and Eisai announce submission of manufactur..
PU
2018NEWRON PHARMACEUTICALS : Announces Prominent Medical Experts to Present at its 2..
AQ
2018NEWRON PHARMACEUTICALS : Announces Prominent Medical Experts to Present at its 2..
AQ
More news
Analyst Recommendations on NEWRON PHARMACEUTICALS SPA
More recommendations
Sector news : Bio Therapeutic Drugs
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Bio Therapeutic Drugs
Chart NEWRON PHARMACEUTICALS SPA
Duration : Period :
Newron Pharmaceuticals SpA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEWRON PHARMACEUTICALS SPA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 27,8 €
Spread / Average Target 321%
EPS Revisions
Managers
NameTitle
Stefan Weber Chief Executive Officer, Director & IR Contact
Ulrich Köstlin Non-Executive Chairman
Roberto Galli Vice President-Finance
Ravi Anand Chief Medical Officer
Patrick J. Langlois Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS SPA28.34%134
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS17.49%49 757
REGENERON PHARMACEUTICALS12.14%44 532
GENMAB-4.59%9 536
NEUROCRINE BIOSCIENCES, INC.28.18%8 300